Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system

References

• Disease GIFCOL 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease https://goldcopd.org/goldreports/:Globa Initiative for Chronic Obstructive Lung Disease
   Google Scholar
• LEE J-H. Pathogenesis of COPD. LEE S-D, editor. COPD: heterogeneity and personalized treatment. Berlin Heidelberg:Springer Berlin Heidelberg; 2017:9.
   Google Scholar
• World Health Organization. (2011, September 14). WHO | burden of COPD. https://www.who.int/respiratory/copd/burden/en/ [Accessed 2019 July 30].
   Google Scholar
• Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000–2016, 2018
   Google Scholar
• Martínez MA, Leiva AM, Petermann F, et al. ¿Cómo ha cambiado el perfil epidemiológico en Chile en los últimos 10 años? Rev Méd Chile. 2021;149(1):149–152.
   PubMedGoogle Scholar
• Soriano JB, Kendrick PJ, Paulson KR, GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Ciapponi A, Alison L, Agustina M, et al. The epidemiology and burden of COPD in Latin America and the Caribbean: systematic review and meta-analysis. COPD. 2014;11(3):339–350.
   PubMedGoogle Scholar
• Sepúlveda R. Las enfermedades respiratorias del adulto mayor en Chile: un desafío a corto plazo. Rev chil de enfermedades respir. 2017;33(4):303–307.
   Google Scholar
• Burrows B, Bloom JW, Traver GA, et al. the course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med. 1987;317(21):1309–1314.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a european respiratory society/American thoracic society guideline. Eur Respir J. 2017;49(3):1600791.
   PubMed Web of Science ®Google Scholar
• Donaldson GC. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387–395.
   PubMed Web of Science ®Google Scholar
• Seemungal T, Donaldson G, Paul E, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422.
   PubMed Web of Science ®Google Scholar
• Jakovljevic MB, Lazic Z, Verhaeghe N, et al. Direct medical costs of COPD diagnosis and treatment, Eastern vs Western European country – examples of Serbia and Belgium. Farmeconomia. Health Economics and Therapeutic Pathways. 2013;14(4):161–168.
   Google Scholar
• Jakovljevic MB, Lazic Z, Gajovic O, et al. GOLD Stage Impact on COPD direct medical costs in elderly. Health Behav & Pub Health 2012 2(3): 1–7, Available at SSRN. https://ssrn.com/abstract=2376771
   Google Scholar
• Iheanacho I, Zhang S, King D, et al. economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460.
   PubMed Web of Science ®Google Scholar
• Reynales LM, Rodríguez R, Jiménez JA, et al. Costos de la atención médica atribuibles al consumo de tabaco en el instituto mexicano del seguro social [health care costs attributable to tobacco consumption on a national level in the Mexican social security institute]. Salud publica de Mexico. 2006;48(1):S48–S64.
   PubMedGoogle Scholar
• Pérez N, Murillo R, Pinzón C, et al. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev Colomb Cancerol. 2007;11(4):241–249.
   Google Scholar
• Perez R, Menezes A. Chronic obstructive pulmonary disease in Latin America. Ann Glob Health. 2019;85(1):7.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;k4388. DOI:https://doi.org/10.1136/bmj.k4388
   Google Scholar
• Lipson DA, Barnhart F, and Brealey N, et al., IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• López Varela MV, Muiño A, Pérez Padilla R, et al., PLATINO Group. Tratamiento de la EPOC en 5 ciudades de América Latina: estudio PLATINO [Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study]. Arch Bronconeumol. 2008;44(2):58–64.
   PubMed Web of Science ®Google Scholar
• Montes de Oca M, Tálamo C, Perez-Padilla R, et al., PLATINO Team. Use of respiratory medication in five Latin American cities: the PLATINO study. Pulm Pharmacol Ther. 2008;21(5):788–793.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud. INFORME FINAL DEL ESTUDIO DE VERIFICACIÓN DEL COSTO ESPERADO INDIVIDUAL PROMEDIO POR BENEFICIARIO DEL CONJUNTO PRIORIZADO DE PROBLEMAS DE SALUD CON GARANTÍAS EXPLÍCITAS 2018 Instituto de Administración de Salud;Updated 2019 November 30 Available from: http://www.ias.uchile.cl/uploads/investigacion_archivo/a741b6c357e54c73af7b165156750280d06fe65e.pdf
   Google Scholar
• Ministerio de Salud. Manual Operativo Programas de Salud Respiratoria. In: Division de Atención Primaria UdSR, editor. 2015 [Updated 2019 November 30] Available from: http://www.bibliotecaminsal.cl/wp/wp-content/uploads/2018/01/011.Manual-operativo-Programas-Salud-respiratoria.pdf
   Google Scholar
• Ministerio de Salud. Guia Clinica AUGE: enfermedad pulmonar Obstructiva Crónica EPOC. In: , editor. http://www.bibliotecaminsal.cl/wp/wp-content/uploads/2016/04/Enfermedad-Pulmonar-Obstructiva-Cr%C3%B3nica.pdf. [Accessed 2019 November 30]
   Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Baker T, and Risebrough NA, et al. Development of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Mak. 2016;37(4):469–480.
   PubMed Web of Science ®Google Scholar
• Tabberer M, Gonzalez-mcquire S, and Muellerova H, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Mak. 2016;37(4):440–452.
   PubMed Web of Science ®Google Scholar
• Exuzides A, Colby C, and Briggs AH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE STUDY. Med Decis Mak. 2015;37(4):453–468.
   PubMed Web of Science ®Google Scholar
• Jones PW, Adamek L, Nadeau G, et al. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2012;42(3):647–654.
   PubMed Web of Science ®Google Scholar
• Bogart M, Wu B, Germain G, et al. REAL-WORLD ADHERENCE TO SINGLE-INHALER VS MULTIPLE-INHALER TRIPLE THERAPY AMONG PATIENTS WITH COPD IN A COMMERCIALLY INSURED US POPULATION. Chest. 2020;158(4):A1773–A1774.
   Web of Science ®Google Scholar
• GlaxoSmithKline & Mapi. (2018). Comparative efficacy of FF/UMEC/VI 100/62.5/25 versus triple therapies for COPD: systemic literature review and network meta-analysis (NMA) results (Canadian analysis, draft report).
   Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, et al. Predicting EQ-5D Values Using the SGRQ. Value Health. 2011;14(2):354–360.
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C and Vestbo J. (2007). Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med, 356(8), 775–789. https://doi.org/10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146(8):545.
   PubMed Web of Science ®Google Scholar
• Paly V, Vallejo-Aparicio LA, Schroeder M, et al. Prs25 the impact trial: is single-inhaler triple therapy (ff/umec/vi) cost-effective versus dual therapy with inhaled corticosteroid plus long-acting beta agonist (ff/vi) in patients with copd in Spain? Value Health. 2019;22:S877.
   Web of Science ®Google Scholar
• Mursleen S, Shah D, Schroeder M, et al. Prs44 - informing the pathway of copd treatment (impact study) - single inhaler triple therapy (ff/umec/vi) versus umec/vi in patients with copd: cost-effectiveness analysis from a societal perspective in quebec. Value Health. 2018;21:S411.
   Google Scholar
• Paly V, Schroeder M, Martin A, et al. Prs24 - informing the pathway of copd treatment (impact study) - single inhaler triple therapy (ff/umec/vi) versus ff/vi and umec/vi in patients with copd: healthcare resource utilization data and associated costs – Germany. Value Health. 2018;21:S407.
   PubMedGoogle Scholar
• Bremner PR, Birk R, Brealey N, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19.
   PubMedGoogle Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Lin C, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548.
   PubMed Web of Science ®Google Scholar
• Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Document Number GM2000/00068/01 Study ID SAS10005. A part-randomized, single-blind, placebo-controlled, five-way crossover study to assess the absolute bioavailability, relative bioavailability and comparative pharmacodynamics of fluticasone propionate from Advair HFA MDI, Advair DISKUS, FP CFC MDI and intravenous FP and to assess the relative bioavailability and comparative pharmacodynamics of salmeterol from Advair HFA MDI to Advair DISKUS. Report Date 2001 Aug 07.
   Google Scholar